Replimune Group, Inc.
REPL
Updated: 23/09/2026, 13:37:05
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
No summaries found.
- Share price
- $13.47
- Market cap
- $1.13B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Sushil Patel
- Employees
- 465
- IPO date
- 20/07/2018
- Beta
- 0.9419999999999999
- Last dividend
- $0.00
- Day range
- $12.80 – $13.62
- 52-week range
- $1.50 – $16.33
- 1-day performance
- 4.66%
- 1-year performance
- 798.00%
- Current drawdown (1Y)
- -17.51%
- CIK
- 0001737953
- CUSIP
- 76029N106
- ISIN
- US76029N1063
- Created
- 07/12/2025, 13:58:01
- Last update
- 23/09/2026, 13:37:05
Track Replimune Group, Inc. with an AI analyst
See which prediction-market events move REPL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Replimune (REPL) Stock Jumps: FDA Resubmission for RP1 Melanoma
Market Data • Market Data • 04/06/2026, 00:00:22
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Zacks Investment Research • STOCK • 01/06/2026, 16:06:13
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
GlobeNewsWire • STOCK • 31/05/2026, 10:00:00
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Globe News Wire • STOCK • 30/05/2026, 10:00:00
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
GlobeNewsWire • STOCK • 30/05/2026, 10:00:00
How Replimune's drug got a third chance after the White House intervened
WSJ • STOCK • 29/05/2026, 23:53:00
Replimune reaches agreement with US FDA to resubmit melanoma drug application
Reuters • STOCK • 29/05/2026, 10:07:19
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
GlobeNewsWire • STOCK • 29/05/2026, 10:00:00
Replimune Gets Third Try at FDA Approval After Makary Departure
WSJ • STOCK • 29/05/2026, 09:30:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
PRNewsWire • STOCK • 21/05/2026, 18:40:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
GlobeNewsWire • STOCK • 19/05/2026, 20:07:00
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
GlobeNewsWire • STOCK • 17/05/2026, 23:49:00